Scarica l'app Stockscreener
0.6002
0.68%
-0.0041
Pre-mercato:
.60
-0.0002
-0.03%
Precedente Chiudi:
$0.6043
Aprire:
$0.5973
Volume 24 ore:
81,579
Relative Volume:
0.03
Capitalizzazione di mercato:
$4.61M
Reddito:
-
Utile/perdita netta:
$-10.31M
Rapporto P/E:
-0.2575
EPS:
-2.3308
Flusso di cassa netto:
$-6.32M
1 W Prestazione:
+14.32%
1M Prestazione:
+0.03%
6M Prestazione:
-34.43%
1 anno Prestazione:
-64.17%
Intervallo 1D:
$0.5824
$0.6173
Intervallo di 1 settimana:
$0.4955
$0.6767
Portata 52W:
$0.4111
$2.34
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Nome
Galmed Pharmaceuticals Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Compare GLMD vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.6002 | 4.73M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-05-22 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Iniziato | Craig Hallum | Buy |
| 2020-01-30 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-08-02 | Reiterato | Maxim Group | Buy |
| 2018-07-13 | Iniziato | Stifel | Buy |
| 2018-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2018-02-14 | Downgrade | Maxim Group | Buy → Hold |
| 2018-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-15 | Iniziato | ROTH Capital | Buy |
| 2017-08-08 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Reiterato | Maxim Group | Buy |
| 2016-08-01 | Reiterato | Maxim Group | Buy |
| 2016-07-06 | Ripresa | ROTH Capital | Buy |
| 2016-03-28 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-06 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
Mostra tutto
Galmed Pharmaceuticals Ltd Borsa (GLMD) Ultime notizie
GLMD Should I Buy - Intellectia AI
GLMD Q4 2025 Earnings: EPS Misses Estimates by Significant MarginEBITDA Analysis - newsline.com
Galmed to acquire Colospan for USD 4.5M - Medical Buyer
Galmed to acquire medical device firm Colospan for $4.5M By Investing.com - Investing.com Australia
Galmed to Acquire Colospan in Deal Expanding GI Medtech Platform - citybiz
Galmed Pharmaceuticals to Acquire Colospan, targeting $6B GI market - grafa.com
Incyte, Galmed, and Johnson & Johnson Announce Acquisitions Totaling $3 Billion - geneonline.com
Galmed to acquire medical device firm Colospan for $4.5M - Investing.com UK
Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion - TipRanks
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - The AI Journal
Galmed Pharmaceuticals (NASDAQ: GLMD) files amendment adding auditor consent - Stock Titan
Galmed (NASDAQ: GLMD) registers 7.5M shares; agrees to buy Colospan - Stock Titan
[6-K] Galmed Pharmaceuticals Ltd. Current Report (Foreign Issuer) | GLMD SEC FilingForm 6-K - Stock Titan
Press Release: Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - Moomoo
Galmed’s $6B bet on Colospan device to ease life after colorectal surgery - Stock Titan
GLMD News | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo - TipRanks
Galmed, Tissue Dynamics report preclinical cardiac fibrosis data By Investing.com - Investing.com South Africa
Galmed (GLMD) and Tissue Dynamics show fourfold fibrosis cut in human heart organoids - Stock Titan
Galmed, Tissue Dynamics report preclinical cardiac fibrosis data - Investing.com
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis - PR Newswire
Galmed Pharmaceuticals (GLMD) Surges 9.35% as Shares Test Key ResistanceOutside Reversal - The Legal Advocate
Galmed Pharmaceuticals (GLMD) Surges 9.5%: Testing Key Resistance at $0.71Momentum Trade - The Legal Advocate
GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
GLMD Q1'26 Earnings: EPS estimate is (0.38) USD - TradingView
Galmed Pharmaceuticals Ltd expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Number of shareholders of Galmed Pharmaceuticals Ltd. – FWB:GPH - TradingView
Galmed Pharmaceuticals Ltd.Ordinary Shares (NQ: GLMD - FinancialContent
TradingKey - TradingKey
Galmed Reports Fivefold Bioavailability Boost with New Aramchol Meglumine Oral Formulation - TipRanks
Galmed reports improved bioavailability in Aramchol study - Investing.com
Galmed reports improved bioavailability in Aramchol study By Investing.com - Investing.com Australia
Aramchol PK study shows fivefold exposure gain, Galmed (NASDAQ: GLMD) says - Stock Titan
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg - PR Newswire
Tissue Dynamics, Galmed partner on cardiac fibrosis model By Investing.com - Investing.com Australia
Tissue Dynamics and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announce a strategic collaboration to jointly develop a chronic cardiac fibrosis research platform focused on human disease models. - Bitget
Galmed (NASDAQ: GLMD) teams with Tissue Dynamics on chronic cardiac fibrosis platform - Stock Titan
Tissue Dynamics, Galmed partner on cardiac fibrosis model - Investing.com
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics - PR Newswire
GLMD (Galmed Pharmaceuticals Ltd. Ordinary Shares) posts wider than expected Q4 2025 loss, shares dip nearly one percent.Meet Estimates - Xã Thanh Hà
Shmuel Nir Net Worth (2026) - GuruFocus
Amir Poshinski Net Worth (2026) - GuruFocus
Brueck Liat Nissimov Net Worth (2026) - GuruFocus
Doron Leib Cohen Net Worth (2026) - GuruFocus
Allen Baharaff Net Worth (2026) - GuruFocus
Yohai Stenzler Net Worth (2026) - GuruFocus
Guy Nehemya Net Worth (2026) - GuruFocus
Galmed Pharmaceuticals (GLMD) Stock: Beginner's Guide (Smart Money Outflows) 2026-04-15Fast Moving Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Galmed collaborates with Tel Aviv University to evaluate targeted therapy for metastatic brain cancers - BioSpectrum Asia
Galmed Pharmaceuticals Ltd. and Ramot At Tel Aviv University Enter Research Collaboration Agreement - marketscreener.com
Galmed partners with Tel Aviv University on brain cancer therapy By Investing.com - Investing.com Australia
Galmed Pharmaceuticals Ltd Azioni (GLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):